About Cymss-Bio

Cymss-Bio manufactures the TASCL microplate, designed for the three-dimensional culture of spheroids, enabling the efficient production of uniform cell aggregates for regenerative medicine applications. The company also provides support services for medical facilities to implement PRP and stem cell therapies, addressing the regulatory and operational challenges associated with adopting these advanced treatments.

```xml <problem> Generating uniform, high-quality spheroids for regenerative medicine and 3D cell culture research is challenging due to inconsistencies in cell aggregate size and the complexities of long-term culture and differentiation. Traditional methods often lack the scalability and ease-of-use required for efficient production and analysis of cell aggregates. </problem> <solution> Cymss-Bio addresses these challenges with TASCL, a microplate designed for three-dimensional cell culture, enabling the efficient and scalable production of uniform spheroids. TASCL microplates facilitate long-term culture, allowing for differentiation studies and advanced cell-based assays. The microplates are designed for ease of use, allowing direct microscopic observation of cells and simplified media exchange. Cymss-Bio also provides support services to medical facilities for the implementation of regenerative medicine therapies, including PRP and stem cell treatments, assisting with regulatory compliance and operational logistics. </solution> <features> - Microfabricated plates designed for uniform spheroid formation and size control - Surface treatment technology promoting cell attachment and spheroid development - Suitable for long-term 3D cell culture and differentiation studies - Compatible with standard microscopy techniques for direct cell observation - Facilitates easy media exchange and reduces overall costs - Application notes available detailing specific protocols and use cases - Support services for regenerative medicine adoption, including regulatory guidance and facility coordination </features> <target_audience> The primary customers include researchers in regenerative medicine, cell biology, and drug discovery, as well as medical facilities (hospitals and clinics) seeking to implement PRP and stem cell therapies. </target_audience> ```

What does Cymss-Bio do?

Where is Cymss-Bio located?

Cymss-Bio is based in Nagoya, Japan.

When was Cymss-Bio founded?

Cymss-Bio was founded in 2018.

Location

Nagoya, Japan

Founded

2018

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Cymss-Bio

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

cymss-bio.com

Founded 2018 – Nagoya, Japan

Funding

No funding information available.

Team

No team information available.

Company Description

Problem

Generating uniform, high-quality spheroids for regenerative medicine and 3D cell culture research is challenging due to inconsistencies in cell aggregate size and the complexities of long-term culture and differentiation. Traditional methods often lack the scalability and ease-of-use required for efficient production and analysis of cell aggregates.

Solution

Cymss-Bio addresses these challenges with TASCL, a microplate designed for three-dimensional cell culture, enabling the efficient and scalable production of uniform spheroids. TASCL microplates facilitate long-term culture, allowing for differentiation studies and advanced cell-based assays. The microplates are designed for ease of use, allowing direct microscopic observation of cells and simplified media exchange. Cymss-Bio also provides support services to medical facilities for the implementation of regenerative medicine therapies, including PRP and stem cell treatments, assisting with regulatory compliance and operational logistics.

Features

Microfabricated plates designed for uniform spheroid formation and size control

Surface treatment technology promoting cell attachment and spheroid development

Suitable for long-term 3D cell culture and differentiation studies

Compatible with standard microscopy techniques for direct cell observation

Facilitates easy media exchange and reduces overall costs

Application notes available detailing specific protocols and use cases

Support services for regenerative medicine adoption, including regulatory guidance and facility coordination

Target Audience

The primary customers include researchers in regenerative medicine, cell biology, and drug discovery, as well as medical facilities (hospitals and clinics) seeking to implement PRP and stem cell therapies.